A potential role for sex hormone receptor antagonists in treatment of malignant salivary gland tumours, as compared to breast cancer: A review of literature  by Omar, T.A. et al.
Available online at www.sciencedirect.comScienceDirect
Tanta Dental Journal 10 (2013) 75e85
www.elsevier.com/locate/tdjA potential role for sex hormone receptor antagonists in treatment of
malignant salivary gland tumours, as compared to breast cancer:
A review of literature
T.A. Omar, F. ElDidi, W.M. Nawar*
Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Alexandria University, EgyptAbstractMalignant salivary gland tumours (MSGTs) account for less than 5% of all cancers of the head and neck. However, their
treatment represents a challenge to oral and maxillofacial specialists. Surgical resection followed by radiation therapy represents
the primary treatment of localized MSGTs. Since breast and salivary glands share similar morphologic features; similarities in the
pathological processes are also expected. Adjuvant hormonal therapy is recommended for breast tumours containing hormone
receptor protein. The expression of sex hormones in MSGTs, and their potential use in treatment is still controversial. This review
article discusses three types of tumours arising in the breast and salivary glands; namely mucoepidermoid carcinoma, adenoid
cystic carcinoma and salivary duct carcinoma. The expression of sex hormone receptor proteins and the potential use of hormone
receptor antagonists in treatment are also being addressed.
 2013, Production and Hosting by Elsevier B.V. on behalf of the Faculty of Dentistry, Tanta University.
Keywords: Malignant salivary gland tumours; Mucoepidermoid carcinoma; Adenoid cystic carcinoma; Salivary duct carcinoma; Sex hormone
receptor; Estrogen receptor; Progesterone receptor; Androgen receptor
Open access under CC BY-NC-ND license.Introduction
Tumours of the salivary glands; although uncom-
mon, constitute an important area in the field of oral* Corresponding author.
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lymphoma and metastatic tumours can also occur
within the salivary glands [1].
Malignant salivary gland tumours (MSGTs) account
for less than 5% of all cancers of the head and neck [2].
The annual incidence rates in the world vary between
slightly less than 2 and greater than 0.05 per 100,000
inhabitants [3].
Surgical resection followed by radiation therapy
represents the primary treatment of localized MSGTs
[4]. However, in some cases, the disease is rapidly
progressive and even metastatic [5]; therefore systemic
adjuvant therapies are necessary. They are designed tothe Faculty of Dentistry, Tanta University.
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76 T.A. Omar et al. / Tanta Dental Journal 10 (2013) 75e85eradicate microscopic deposits of cancer cells that may
have spread or metastasized from the primary tumour
[4].
Breast and salivary glands share similar morpho-
logic features; consequently it is reasonable to expect
similarities in the pathological processes [6]. Adjuvant
hormonal therapy is recommended for breast tumours
that contain hormone receptor protein [7]. However the
expression of sex hormones in MSGTs and their po-
tential use in treatment is still controversial [4].
This review article addresses the following key
points
1. Classification of MSGTs
2. Similarities between MSGTs and Breast Cancers
a. Mucoepidermoid Carcinoma
b. Adenoid Cystic Carcinoma
c. Salivary/Mammary Duct Carcinoma
3. Role of hormones in treatment of breast cancers
4. Expression of sex steroid hormones in MSGTs
5. The potential role of hormones in treatment of
MSGTs1. Classification of MSGTs
The World Health Organization (WHO) in 2005
classified malignant epithelial tumours as follows [8]:1. Acinic cell carcinoma
2. Mucoepidermoid carcinoma
3. Adenoid cystic carcinoma
4. Polymorphous low-grade adenocarcinoma
5. Epithelial-myoepithelial carcinoma
6. Clear cell carcinoma, not otherwise specified
7. Basal cell adenocarcinoma
8. Malignant sebaceous tumours
9. Cystadenocarcinoma
10. Low-grade cribriform cystadenocarcinoma
11. Mucinous adenocarcinoma
12. Oncocytic carcinoma
13. Salivary duct carcinoma
14. Adenocarcinoma, not otherwise specified
15. Myoepithelial carcinoma
16. Carcinoma ex pleomorphic adenoma
17. Carcinosarcoma
18. Metastasizing pleomorphic adenoma
19. Squamous cell carcinoma
20. Small cell carcinoma
21. Large cell carcinoma
22. Lymphoepithelial carcinoma
23. Sialoblastoma2. How are MSGTs similar to breast cancers?
Breast and salivary glands are both tubulo-acinar
exocrine glands with similar morphologic features.
The same types of neoplasms can arise in both sites;
such as pleomorphic adenoma, myoepithelioma, acinic
cell carcinoma, oncocytic carcinoma [6], mucoepi-
dermoid carcinoma (MEC) [9], adenoid cystic carci-
noma (AdCC) [10], and salivary duct carcinoma (SDC)
[11].In this review, three types of tumours are discussed;
MEC, AdCC and SDC. These tumours are not only
similar to breast cancers in terms of morphologic and
biologic characteristics, but also at the molecular level
[4]. They have also been evaluated for their expression
of sex hormone receptor proteins in several studies
[12e24].
2.1. Mucoepidermoid carcinoma
Mucoepidermoid Carcinoma of the salivary gland is
one of the most common types of MSGTs, accounting
for 29e34% of all MSGTs. They occur over a wide age
range, from the 2nd to the 7th decades, with slight
female predilection. They are the most common
MSGTs to occur in children, most commonly affecting
the parotid gland [1].
i. Histologically
It is composed of a mixture of mucous, epidermoid
and intermediate cells. Some tumours also show vari-
able numbers of clear cells. Mucous cells vary in shape
but contain abundant foamy cytoplasm. Epidermoid
cells are polygonal in shape and have intercellular
bridges. The intermediate cells are the progenitor cells
of both types. They vary from small basaloid cells to
large ovoid cells with pale eosinophilic cytoplasm [1].There are three histopathologic grades; low, inter-
mediate and high grades, according to relative number
of mucous and epidermoid cells, amount of cyst for-
mation and cytologic atypia [1].
Low grade tumours show prominent cyst formation,
and a high proportion of mucous cells. High grade
tumours consist of solid islands of squamous and in-
termediate cells. Intermediate tumours have a rela-
tively equal number of mucous and squamous cells
[1].Fig. 1
Fig. 1. Ref. [25] A: Intermediate-grade MEC showing limited cyst formation and nearly absent mucocytes. B: A high-grade tumour with mitoses
and profound pleomorphism.
77T.A. Omar et al. / Tanta Dental Journal 10 (2013) 75e85ii. Prognosis and treatment
Prognosis depends on the grade and stage of the
tumour. Generally 90e98% of the patients are cured.
Submandibular gland tumours have worse prognosis
than parotid tumours.
Surgical resection of the involved gland and post-
operative radiation therapy is the main line of treat-
ment [1].
On the other hand, Mucoepidermoid Carcinoma of
the Breast is very rare entity with an estimated inci-
dence of 0.2% [6].Fig. 2. Ref. [6] E: Low grade mammary mucoepidermoid carcinoma (MEC)
containing epidermoid and mucous secreting cells; F: high power magnifica
basaloid and epidermoid elements and mucous secreting cells.i. Histologically
Mucoepidermoid carcinoma of the breast can also
be categorized as low, intermediate and high grades.
Low grade MEC discloses well circumscribed, some-
times cystic lesions, filled with mucins. Neoplastic
nests and cysts are lined at the periphery by basaloid
cells and intermediate cells. Epidermoid or mucous
secreting cells are usually found in the central aspects
[6].
High grade breast MEC encompasses different en-
tities of high histological grade, which are composedcomposed of neoplastic nests outlined by basaloid cells and centrally
tion of high grade mammary MEC showing a complex admixture of
78 T.A. Omar et al. / Tanta Dental Journal 10 (2013) 75e85of a complex admixture of glandular structures with
mucin production, foci of squamous differentiation,
and so called intermediate cells, with a pronounced
predominance of the squamous and intermediate cell
components [26].Fig. 2
ii. Prognosis and treatment
Because of the rarity, the prognosis of MEC of the
breast is still controversial [9].
iii. On the molecular level
A reciprocal translocation t(11; 19) (q21; p13)
(MAML2:MECT) was shown in breast MEC, which is
known as the most frequent genetic alteration of sali-
vary MEC [27].
2.2. Adenoid cystic carcinoma
Adenoid cystic carcinoma (AdCC), formerly known
as cylinderoma, is a form of adenocarcinoma that af-
fects minor and major salivary glands, lacrimal glands,
excretory glands of the female genital tract [28] and
the breast [6].
Adenoid cystic carcinoma of the salivary gland is
one of the most common minor salivary gland tumours,
accounting for 22% of all head and neck tumours [29],
with the palate being the primary site affected. AdCC
represents 8e15% of all palatal salivary neoplasms. It
is common between the 5th and 7th decades with slight
female predilection [1].
Adenoid cystic carcinoma is a slowly growing mass,
firm on palpation and it is characterized by pain due to
perineural sheath invasion [1].Fig. 3. Ref. [31] a: Low-grade adenoid cystic carcinoma of the salivary glan
cystic carcinoma of the salivary gland with greater than 30% solid patterni. Histologically
Adenoid cystic carcinoma is composed of two main
types of cells; myoepithelial and ductal cells. Three
histologic patterns can be recognized: the cribriform,
the tubular-trabecular and the solid patterns [30].
In the cribriform pattern, islands of basaloid epithe-
lial cells contain cyst-like spaces resembling Swiss
cheese. These spaces often contain a mildly basophilic
mucoid material and a hyalinised eosinophilic product.
Tumour cells are small and cuboidal, exhibiting deeply
basophilic nuclei and little cytoplasm [28].
In the tubular pattern, there are duct-like spaces.
These spaces are lined by one to several layers of the
tumour cells [1].
The solid variant consists of large islands or sheets
of tumour cells. Unlike the cribriform and tubular
patterns, cellular pleomorphism, mitotic activity and
focal necrosis in the centre of the tumour islands may
be observed [1].Fig. 3
ii. Immunohistochemically
Positive immunostaining reactions to CD43 and c-kit
(CD117) have proven useful in diagnosing AdCC [32].
Some other markers have been suggested to be
diagnostically relevant; such as vimentin, collagen IV,
laminin, integrins, ki-67, smooth muscle actin, and
various cytokeratins [1].
iii. Prognosis and treatment
Adenoid cystic carcinoma is prone to local recurrence.
Eventual distant metastases occur in 35% of the patients.
Metastatic spread most commonly occurs to the lungsd with predominant cribriform/tubular pattern. c: High-grade adenoid
.
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lymph nodes. Prognosis is poorer for the solid type.With
respect to the site, it is poorest for tumours affecting the
maxillary sinus and submandibular glands [1].
Surgical excision is usually the treatment of choice,
followed by adjunct radiation therapy. The 5, 10 and
20-year survival rates are 70%, 50% and 25% respec-
tively [33].
On the other hand, adenoid cystic carcinoma of the
breast is rare; representing 0.1e1% of all breast neo-
plasms [9]. It usually affects adult female patients [33]
ranging from 38 to 81 years. It presents as a nodule
0.7e12 cm in diameter, frequently located in the per-
iareolar region [6].
i. Histologically
Adenoid cystic carcinoma of the breast is composed
of large sheets, nests or small aggregates of round to
oval cells, sometimes with hyperchromatic nuclei. It
might show areas of squamous differentiation; also
sebaceous features can be found [34].
Three histologic patternsesimilar to those of
AdCC of the salivary glandecan be recognized: the
cribriform, the tubular-trabecular and the solid pat-
terns [6].
Also two types of spaces characterize AdCC of the
breast. The first space contains myxoid stroma or
collagen fibres. The second space is composed of
glands that contain a granular secretion of Periodic
Acid Schiff positive mucosubstances [6].
These spaces are lined by two types of cells; basa-
loid cells, with central oval nuclei surrounded by a thin
cytoplasmic rim, and the second type characterized by
round nuclei and eosinophilic cytoplasm [6].Fig. 4Fig. 4. Ref. [6] C: Adenoid cystic carcinoma of the breast showing solid an
cells that outline spaces containing basal-like material and of eosinophilic c
(SMA) demonstrates myoepithelial cells.ii. Immunohistochemically
Immunostaining reactions of basaloid cells are
positive for vimentin and CK14 and focally for
myoepithelial markers, such as smooth muscle actin,
calponin, p63 and maspin [6].
iii. Prognosis and treatment
Adenoid cystic carcinoma of the breast is not
aggressive. The prognosis is usually good. Local re-
currences and axillary lymph node metastasis are rare.
Distant metastasis is uncommon and usually affects the
lungs. Simple mastectomy with no axillary dissection
is the treatment of choice [6].
iv. On the molecular level
AdCC of the breast share similar chromosomal
abnormalities with AdCC of the salivary glands;
including alterations in the 6q arm [35]. The genetic
translocation t(6; 9) (q22-23; p23-24) is characteristic
for salivary AdCC [36], and is also detected in breast
AdCC [37].
2.3. Salivary/mammary duct carcinoma
Salivary duct carcinoma is a rare highly aggressive
neoplasm [4].
i. Histologically
The epithelium tends to form cribriform, papillary
and solid growth patterns along with duct-like struc-
tures. The morphology of SDC is characterized byd cribriform architecture; inset, breast ACC is composed of basaloid
ells lining true glandular lumina; D: staining for smooth muscle actin
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often with central necrosis [4].Fig. 5
ii. Immunohistochemically
Her2 expression is demonstrated in SDC and since
Her2 can enhance androgen receptor (AR) function,
antiandrogen therapy may be more effective against
MSGTs when Her2 is overexpressed [39].
iii. Prognosis and treatment
Generally SDC shows less survival rates than other
MSGTs [4].
On the other hand, mammary duct carcinoma com-
prises a heterogeneous group of lesions with diverse
malignant potential. Most patients present with lumps
that are not palpable and are clinically occult [40].
i. Histologically
Ductal carcinoma in situ is a proliferation of ma-
lignant epithelial cells within the ductolobular system
of the breast that show no light microscopic evidence
of invasion through the basement membrane into the
surrounding stroma. Several forms of histological ar-
chitecture are recognised, the most common of whichFig. 5. Ref. [38] A number of different patterns of growth can be seen. A
renchyma. B: Papillary pattern. C: A more solid pattern of growth is note
sarcomatoid pattern to the cells that are infiltrating into the adjacent fat anare comedo, cribriform, solid, micropapillary and
papillary [41].Fig. 6
ii. Prognosis and treatment
The rates for mortality and the risk of invasive
recurrence at eight years are 1.4% and 7% respectively.
Current treatments for ductal carcinoma in situ range
from simple tumour excision, to various forms of wider
excision to mastectomy. All treatments less than mas-
tectomy may be followed by radiotherapy [41].
iii. On the molecular level
There are similar alterations on chromosomal arms
6q, 16q, 17p and 17q in both salivary and mammary
duct carcinomas [11].
3. Role of sex hormones in treatment of breast
cancer
Estrogen promotes the growth of about 2 out of 3 of
breast cancers; estrogen receptor (ER) positive cancers
[43]. Because of this, several approaches to blocking
the effect of estrogen or lowering estrogen levels are
used to treat hormone receptor-positive breast cancers
[44].: A micropapillary architecture infiltrating into the surrounding pa-
d, composed of large, polygonal tumour cells. D: This area shows a
d parenchyma.
Fig. 6. Ref. [41] A: Comedo-type ductal carcinoma in situ, HE stains. B: Cribriform-type ductal carcinoma in situ. C: Solid-type ductal carcinoma
in situ. D: Papillary-type ductal carcinoma in situ.
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reduction in the recurrence rate and in the breast
cancer death rate are highly significant, both in
the trials of 1e2 years of tamoxifen, an ER-antago-
nist, and in those of 5 years of tamoxifen, but are
significantly greater in the latter. However, there
seems to be no significant benefit in ER-negative
women [45].
There are several strategies for treatment of ER-
positive breast cancer [46]:
i. Blocking ovarian function
Ovarian ablation can be done surgically through an
operation to remove the ovaries or by treatment with
radiation. This has a permanent effect.
Alternatively, ovarian function can be suppressed
temporarily by treatmentwith drugs called gonadotropin-
releasing hormone (GnRH) agonists, which are also
known as luteinizing hormone-releasing hormone (LH-
RH) agonists. These medicines interfere with signals
from the pituitary gland that stimulate the ovaries to
produce estrogen.Examples of ovarian suppression drugs that have
been approved by the U.S. Food and Drug Adminis-
tration (FDA) are goserelin (Zoladex) and leuprolide
(Lupron).
ii. Blocking estrogen production
Aromatase inhibitors are used to block the activity of
aromatase,which is used by the body tomake estrogen in
the ovaries and in other tissues. Aromatase inhibitors are
used primarily in postmenopausal women because the
ovaries in premenopausal women produce too much
aromatase for the inhibitors to block effectively. How-
ever, these drugs can be used in premenopausalwomen if
they are given together with a drug that suppresses
ovarian function.
iii. Blocking estrogen’s effects
Several types of drugs interfere with estrogen’s
ability to stimulate the growth of breast cancer cells.
Selective estrogen receptor modulators (SERMs) bind
to estrogen receptors, preventing estrogen from binding.
Table 2
Summary of the reports of estrogen receptor (ER), progesterone re-
ceptor (PR) and androgen receptor (AR) in mucoepidermoid
carcinoma.
Author Year No. of cases ERþ PRþ ARþ
Lamey et al. [21] 1987 1 0 0 np
Jeannon et al. [13] 1999 10 3 0 np
Moriki et al. [15] 2001 8 np np 0
Nasser et al. [16] 2003 10 1 1 2
Pires et al. [17] 2004 136 0 np np
Ito et al. [19] 2009 30 0 0 2
TOTAL 4/187 1/51 4/48
2.1% 2% 8.3%
np: not performed.
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tamoxifen (Nolvadex). Tamoxifen has been used for
more than 30 years to treat hormone receptor-positive
breast cancer.
Hormone therapy can be used as:
1. Adjuvant therapy for early-stage breast cancer to
increase the likelihood of a cure [47].
2. Treatment of metastatic breast cancer: Several
types of hormone therapy are approved to treat
metastatic hormone-sensitive breast cancer [48].
3. Neoadjuvant treatment of breast cancer: The use
of hormone therapy to treat breast cancer before
surgery (neoadjuvant therapy) has been studied in
clinical trials. The goal of neoadjuvant therapy is to
reduce the size of a breast tumour to allow breast-
conserving surgery [49].
4. Prevention of the development of breast cancer in
high risk women; since most early breast cancers
are ER-positive [50].
4. Expression of sex steroid hormones in MSGTs
Human breast cancer [51] and human colorectal
cancer [52] have shown the presence of steroid re-
ceptors to estrogen and progesterone. Evidence is
accumulating concerning other hormone dependant
malignancies including lymphoblastic leukaemia [53],
cancer of the prostate [54], endometrial cancer [55]
and other solid tumours [56].
In salivary gland tumours, expression of estrogen
receptor (ER), progesterone receptor (PR) and androgen
receptor (AR) have been studied [12e24]. There is
substantial disparity in the reported results. This could
be attributed to variations in the technique employed;
such as tissue fixation, sensitivity and specificity of an-
tibodies used and antigen retrieval. In addition, someTable 1
Summary of the reports of estrogen receptor (ER), progesterone re-
ceptor (PR) and androgen receptor (AR) in adenoid cystic carcinoma.
Author Year No. of cases ERþ PRþ ARþ
Shick et al. [12] 1995 12 0 6 0
Jeannon et al. [13] 1999 6 3 0 np
Dori et al. [14] 2000 27 0 2 np
Moriki et al. [15] 2001 6 np np 0
Nasser et al. [16] 2003 10 0 0 2
Pires et al. [17] 2004 72 0 np np
Miller et al. [18] 2004 5 0 np np
Ito et al. [19] 2009 30 0 0 2
Riad S. [20] 2009 11 0 1 8
TOTAL 3/173 9/96 12/69
1.73% 9.4% 17.4%
np: not performed.differences may be related to the criteria adopted for
judging a tumour positive for the marker [16,19].
Tables 1e3 summarize the reports of ER, PR and
AR in Adenoid Cystic Carcinoma (ACC), Mucoepi-
dermoid Carcinoma (MEC) and Salivary Duct Carci-
noma (SDC) respectively.
Most of these studies [12e24] do not support a role
for ER and PR in AdCC, MEC and SDC. However,
SDC expresses AR in the majority of patients
[16,22e24]. Thus immunostaining for AR on cytologic
smears is useful for the diagnosis of these patients [15].
It was also suggested that the high expression of AR in
SDC may play a role in tumour progression [11]. This
may assist in triaging patients with SDCs for novel
therapies1 [15].
5. What is the potential role of hormones in
treatment of MSGTs
To date, no phase II trials have been performed, so it
is difficult to define the role of hormone therapy in
MSGTs [5].
Elkin and Jacobs [57] in 2008 reported partial
remission of two cases of AdCC in which tamoxifen,
an ER antagonist, was used. Both patients obtained
long-term stability of disease with no associated
toxicity.Table 3
Summary of the reports of estrogen receptor (ER), progesterone re-
ceptor (PR) and androgen receptor (AR) in salivary duct carcinoma.
Author Year No. of cases ERþ PRþ ARþ
Fan CY [22] 2000 13 np np 9
Fan CY [23] 2001 12 np np 11
Nasser [16] 2003 10 0 0 6
Williams [24] 2007 84 np np 56
TOTAL 0/10 0/10 82/119
0 % 0 % 68.9%
np: not performed.
Fig. 7. Ref. [58]: A: Local recurrence before treatment, B: After 2
months with androgen-deprivation therapy.
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available for AdCC, and because of the low toxicity of
ER antagonists; therefore, such treatment is recom-
mended for its potential disease-stabilizing effects
[24].
In 2003, Locati et al. [58] reported complete
remission of a recurrent case of AR-expressing
adenocarcinoma in the parotid gland. The 73-year old
patient received a complete anti-androgen blockade
with monthly triptorelin and bicalutamide. Skin lesions
reduced rapidly, until disappearance 2 months later.Complete remission was confirmed by a CT scan
(Fig. 7) [58].
In conclusion, MSGTs refractory to conventional
therapy would possibly benefit from hormonal ther-
apy [17].
6. Recommendations
1. Further studies concerning the expression of sex
hormone receptors in MSGTs need to be evaluated
with greater numbers of samples.
2. Standard protocols for such studies should be
clarified by an approved organization to allow for
meta-analysis.
3. Clinical trials may be conducted eafter patients’
consents- in advanced cases, when the disease is
refractory to conventional treatment modalities.
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